Vetr lowered shares of Gilead Sciences (NASDAQ:GILD) from a strong-buy rating to a buy rating in a research report report published on Wednesday morning. They currently have $90.00 price objective on the biopharmaceutical company’s stock.
A number of other research firms also recently commented on GILD. BMO Capital Markets reiterated a hold rating and issued a $82.00 target price on shares of Gilead Sciences in a report on Friday, October 20th. JPMorgan Chase & Co. set a $85.00 target price on shares of Gilead Sciences and gave the stock a buy rating in a research report on Wednesday, October 25th. Morgan Stanley reissued an equal weight rating and issued a $83.00 target price (up from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. Bank of America dropped their target price on shares of Gilead Sciences from $87.00 to $86.00 and set a neutral rating on the stock in a research report on Wednesday, October 4th. Finally, Zacks Investment Research downgraded shares of Gilead Sciences from a hold rating to a sell rating in a research report on Wednesday, October 18th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have given a buy rating to the company’s stock. Gilead Sciences currently has an average rating of Buy and an average price target of $85.53.
Shares of Gilead Sciences (NASDAQ:GILD) opened at $80.98 on Wednesday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a market cap of $105,781.67, a P/E ratio of 9.22, a P/E/G ratio of -1.76 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same period in the previous year, the firm earned $2.75 EPS. The business’s revenue for the quarter was down 13.2% on a year-over-year basis. analysts predict that Gilead Sciences will post 8.53 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.57%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s payout ratio is presently 23.69%.
In related news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the transaction, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James R. Meyers sold 100,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the completion of the sale, the executive vice president now owns 102,715 shares of the company’s stock, valued at $8,241,851.60. The disclosure for this sale can be found here. Insiders have sold 591,666 shares of company stock worth $44,466,567 over the last ninety days. 1.30% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC lifted its stake in Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares during the last quarter. Vanguard Group Inc. lifted its stake in Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares during the last quarter. Northern Trust Corp lifted its stake in Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after acquiring an additional 116,780 shares during the last quarter. Toronto Dominion Bank lifted its stake in Gilead Sciences by 19.0% in the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after acquiring an additional 75,364 shares during the last quarter. Finally, Fagan Associates Inc. lifted its stake in Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after acquiring an additional 845 shares during the last quarter. Hedge funds and other institutional investors own 75.95% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thestockobserver.com/2018/01/21/gilead-sciences-gild-cut-to-buy-at-vetr.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.